Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,331 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT06608940 |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Case Comprehensive Cancer CenterOTHER |
| 1 |
| Feb 19, 2026 |
| clinicaltrials |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma(PRISM) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of RochesterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Mar 23, 2023 | clinicaltrials |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | Guangdong GD Kongming Biotech LLCINDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol(LIDA-ADJ) | withdrawn | Phase 2 | 0 | University Hospital, MontpellierOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Lion TCR Pte. Ltd.INDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | withdrawn | Phase 2 | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma(TheraBionics) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03484962 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00020774 | SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2020 | clinicaltrials |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients | withdrawn | Phase 2 | 0 | A2 Healthcare Taiwan CorporationINDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | withdrawn | Phase 2 / Phase 3 | 0 | Shi MingOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma(LD-FOX4/HCC) | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2026source: clinicaltrials